Gillian A. Hawker

Jun 4, 2024 | acrjournals.onlinelibrary.wiley.com | Holland Bone |Bindee Kuriya |Gillian A. Hawker |Lihi Eder

INTRODUCTION Treating patients with gout to a target serum uric acid (SUA) level of <360 μmol/L or 6 mg/dL (ie, treatment to target [T2T]) using urate-lowering therapy (ULT) has been associated with decreased flares, reductions in tophi, and improved quality of life.1-5 As such, this approach has been endorsed in the 2020 American College of Rheumatology (ACR) and 2016 EULAR guidelines.6, 7 Additionally, a timeframe of 12 months has been recommended within the ACR's electronic clinical...

Aug 17, 2023 | acrjournals.onlinelibrary.wiley.com | Gillian A. Hawker

Supporting Information Filename Description acr25202-sup-0001-Disclosureform.pdfPDF document, 160.8 KB Disclosure Form

Jul 25, 2023 | onlinelibrary.wiley.com | Gillian A. Hawker

Editorial This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/art.42659.

Jul 24, 2023 | onlinelibrary.wiley.com | Gillian A. Hawker

Editorial This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/acr.25202.

Jul 24, 2023 | pericles.pericles-prod.literatumonline.com | Gillian A. Hawker

Editorial This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/art.42659. Get access to the full version of this article. View access options below.